Calidi Biotherapeutics Financials - Benzinga

Calidi Biotherapeutics Inc

CLDIAMEX

Trade with Public

Trade with Public

$1.13

-0.07-5.83%

가까이에: Sep 25, 5:00 PM EST

$1.13

N/A

시간외: Sep 25, 7:27 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 주식 보고서

Calidi Biotherapeutics Financials

Calidi Biotherapeutics (CLDI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.94) per share. This is a 47.74 percent decrease over losses of $(1.99) per share from the same period last year.

Benzinga Newsdesk

PRO
Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(1.56) by 72.44 percent. This is a 80.09 percent increase over losses of $(2.16) per share

Benzinga Newsdesk

PRO
Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share

Benzinga Newsdesk

Nasdaq Down 1%; Lowe's Posts Upbeat Earnings

Avi Kapoor

Dow Surges 100 Points; Target Shares Fall After Q2 Results

Avi Kapoor

PRO
Calidi Biotherapeutics Q2 EPS $(1.99) Misses $(0.11) Estimate

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(0.11) by 1709.09 percent. This is a 88.12 percent increase over losses of $(16.75) per

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved